A drug designed with artificial intelligence called rentosertib shifted blood protein patterns toward a lower predicted biological age in people with idiopathic pulmonary fibrosis, according to a stud…
An AI-designed drug, rentosertib, developed by Insilico Medicine for idiopathic pulmonary fibrosis, showed signs of reducing biological age in a 12-week phase 2a clinical trial, according to findings …
Insilico Medicine's AI-designed drug rentosertib showed in a 12-week clinical trial that all 42 participants with idiopathic pulmonary fibrosis had reduced predicted ages across six different aging cl…
An experimental AI-designed drug, rentosertib, developed by Insilico Medicine to treat idiopathic pulmonary fibrosis (IPF), appeared to reverse biological-age markers by up to six years in a small hum…
An AI-designed drug, Rentosertib, appeared to make patients biologically younger across six ageing clocks in a small trial of idiopathic pulmonary fibrosis, according to research published in Nature B…
Insilico Medicine's AI-discovered drug rentosertib reduced biological age in a midstage study of 42 patients with chronic lung disease, as measured by six aging clocks, according to an analysis publis…
Insilico Medicine's AI-designed drug rentosertib reduced biological age markers across six AI-powered aging clocks in a 43-patient trial for idiopathic pulmonary fibrosis, results published in Nature …
A study published in Nature Biotechnology reports that Insilico Medicine's AI-generated drug rentosertib reduced biological age markers in 42 patients over a 12-week trial, as measured by six aging cl…
Insilico Medicine's AI-designed drug rentosertib reversed biological aging markers in a 42-patient early trial, with six aging clocks predicting treated patients were up to six years younger biologica…
A developer built a three-task evaluation framework for RNA velocity trajectory inference, measuring global ordering, pairwise rank preservation, and robustness to missing branches on pancreatic endoc…